IPM Take
Fast Track is not approval. That distinction matters. But it is still a serious signal. Givastomig sits at the intersection of three access gates: HER2-negative disease, CLDN18.2 positivity and PD-L1 positivity. If this programme moves into a registrational phase 3 trial, gastric cancer pathways will need more than chemotherapy choice. They will need biomarker logistics that work before first-line treatment begins.
Executive Summary
NovaBridge Biosciences announced that FDA granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinoma whose tumours are both CLDN18.2-positive and PD-L1-positive. Givastomig is a CLDN18.2 x 4-1BB bispecific antibody. NovaBridge said a registrational phase 3 trial is expected to begin as early as the fourth quarter of 2026, with detailed phase 1b data expected at a major medical conference in the second half of 2026.
Why it matters
- Regulators: Fast Track may support closer FDA interaction and more efficient development, but does not establish approval or clinical benefit.
- Pathology: CLDN18.2 and PD-L1 testing could become critical if this pathway advances.
- Clinicians: First-line gastric cancer decision-making is becoming more biomarker-layered.
- Patients: Faster development matters only if the diagnostic pathway can identify who may actually be eligible.
Gastric cancer is becoming a test of how much biomarker complexity health systems can handle before first-line treatment starts.
Not long ago, the question was broad: chemotherapy, immunotherapy, HER2-directed treatment where relevant. Now the pathway is becoming more granular. HER2 status, PD-L1 status, CLDN18.2 expression and emerging bispecific strategies are all pushing into the same decision space.
Givastomig’s Fast Track Designation is therefore not only a regulatory headline. It is a readiness warning. The therapy is being developed for a very specific group: previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinoma with tumours that are both CLDN18.2-positive and PD-L1-positive.
That eligibility stack matters. If the trial programme succeeds, patients will not reach treatment through diagnosis alone. They will reach it through testing, timing and interpretation. If CLDN18.2 testing is not available, if PD-L1 reporting is delayed, or if first-line decisions are made before the full biomarker picture is known, the pathway loses precision before it starts.
The tone should stay disciplined. Fast Track is not a guarantee. It is an FDA mechanism intended to facilitate development and expedite review for serious conditions with unmet need. NovaBridge still has to generate the evidence. But the access signal is already visible.
For IPM, this is a classic personalised medicine story: the treatment is investigational, but the system problem is real now. Gastric cancer care is moving toward deeper biomarker selection. The question is whether health systems can keep up.
